From The Economic Times · Teena Thacker · · 1m 20s
Govt Caps Anti-Cancer Drugs Trade Margins at 30% of MRP
Government to cap anti-cancer drug trade margins at 30% of MRP to reduce prices.
In brief
Government to cap anti-cancer drug trade margins at 30% of MRP to reduce prices. The Indian government plans to cap trade margins for non-scheduled anti-cancer drugs at 30% of MRP to lower patient costs and curb excessive markups. Originally reported by The Economic Times.
Government Prepares Trade Margin Cap
The government is preparing to identify anti-cancer medicines for a proposed 30% trade-margin cap under the Drug Price Control Order.
NPPA Analysis Shows High Markups
NPPA analysis found non-scheduled anti-cancer medicines carry an average trade mark-up of 170%, with mark-ups reaching up to 700% in some cases.
Expert Committee Deadline
An expert committee under DGHS will submit its report by October 14 to recommend anti-cancer drugs covered under the trade margin rationalisation.
Trade Margin Rationalisation
The NPPA approved in principle the proposal to cap trade margins at 30% for identified non-scheduled anti-cancer medicines under Paragraph 19 of the Drug Price Control Order.
Market Impact and Savings
The proposed exercise is expected to reduce MRP by 20, 70% and generate annual savings of around Rs 2,500 crore.
Benefits for Patients
The move aims to reduce patients' out-of-pocket expenditure, improve affordability, curb excessive trade mark-ups, and increase price transparency.
The short version
The Indian government plans to cap trade margins for non-scheduled anti-cancer drugs at 30% of MRP to lower patient costs and curb excessive markups.
